Company profile: Genticel
1.1 - Company Overview
Company description
- Provider of therapeutic vaccines and innovative immunotherapies to treat virus infections and virus-induced diseases, with an initial focus on HPV and HPV-induced conditions, including prevention of cervical cancer in HPV-infected women.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Genticel
Proof Diagnostics
HQ: United States
Website
- Description: Provider of life sciences tools, diagnostics, and computational discovery solutions, offering a smart, portable CRISPR-based and other technology diagnostic system for rapid, low-cost, sensitive detection of infectious diseases (e.g., SARS-CoV-2, Flu A/B, RSV) and other diseases, OMEGA libraries of RNA-programmable non-Cas enzymes for genome engineering, and gene therapy services leveraging these tools.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proof Diagnostics company profile →
Micreos
HQ: The Netherlands
Website
- Description: Provider of phage-based precision antimicrobials and engineered endolysins targeting pathogenic bacteria without harming the beneficial microbiome. Offerings include antimicrobial vectors; MEndoB for staphylococcal infections, including MRSA, for systemic/topical use; XZ.700 for S. aureus colonization in lesional skin (CTCL); and clinical/pre-clinical molecules for out-licensing, with focus areas including CTCL and AD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micreos company profile →
Armata Pharmaceuticals
HQ: United States
Website
- Description: Provider of bacteriophage-based therapeutics, including AP-PA02 for Pseudomonas aeruginosa respiratory infections, AP-SA02 for drug-resistant Staphylococcus aureus (MRSA/VRSA), and AP-PA03 for P. aeruginosa pneumonia, plus a proprietary synthetic phage engineering platform, phage discovery and phenotyping, and bioinformatics-enabled phage analyses to enhance efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Armata Pharmaceuticals company profile →
Anacor Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule therapeutics based on a boron chemistry platform, focused on developing topical treatments for fungal, bacterial, and inflammatory diseases, including its primary product candidate AN2690, a novel topical antifungal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anacor Pharmaceuticals company profile →
Excelimmune
HQ: United States
Website
- Description: Provider of fully human recombinant polyclonal antibodies for therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Excelimmune company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Genticel
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Genticel
2.2 - Growth funds investing in similar companies to Genticel
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Genticel
4.2 - Public trading comparable groups for Genticel
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →